XTNT on a massive sell-off, i can't find any reason.somebody manipulated? DD sayin exactly the opposite : http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127184979&txt2find=xtnt

ICNV 0026 +8% * 46m float * per TA today! Bottom bounce ticket

ANAD Down 60% per net assets+cash worth .5+ imo

TWDL, .0008 -60%

CUBA will bounce eventually.

Bounce plays LIQD ECIG STEM.

MLCG 0007 180M O/S BOTTOM BOUNCER >>>>>>>>>>>>>>>>>>>>>>>>>>>>>

$OCEE - does it have potential as a bounce play - in your opinion

IFON Reversal on going. Bounce in progress!!
Not to late to get in for the earnings ride.

$POIL alert went well yesterday.

$POIL Like Exxon Valdez today. Bounce watch.

SREH bounce coming pr expected shortly

ASKE 0019 bounce start >>>>

$MRIB on high bounce alert for today
!

FRCN 0007 +40% BOUNCE CHART >>>>

$FEGR / BOUNCE

!!!FEGR READY!!!

http://www.barchart.com/chart.php?sym=FEGR&style=technical&template=&p=DO&d=L&sd=&ed=&size=M&log=0&t=BAR&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&sh=100&indicators=&addindicator=&submitted=1&fpage=&txtDate=#jump

!!!0,0011!!!

!!!BID/ASK!!!

!!!0,0011 / 0,0016!!!

FEGR TIME FOR BOTTOM BOUNCE BREAKOUT!!!

Hah - just noticed this is a dead board.

JCP - I know it's a falling knife, but it's gotta bounce pretty soon.

Slo Stoc and RSI at all-time lows.

$SMAK charts, ready for reversal?

PSWS -48% .0085x.009 NO promo

Shares Outstanding 469,574,279 a/o Nov 16, 2012

$SITS .0053 * .0059


----------------------------------------------------------
DD Notes
----------------------------------------------------------


recent news/filings

Feb 14, 2013 Southern ITS International, Inc. in Final Negotiations for Contract With Evitts Resort LLC
read full: http://finance.yahoo.com/news/southern-international-inc-final-negotiations-140000093.html
**********************************************************

Feb 13, 2013 Southern ITS International, Inc. Is Awarded a Significant Network Infrastructure Contract
read full: http://finance.yahoo.com/news/southern-international-inc-awarded-significant-130000743.html
**********************************************************

Feb 12, 2013 Southern ITS International, Inc. Enters Into an Agreement With VxStream
read full: http://finance.yahoo.com/news/southern-international-inc-enters-agreement-192035322.html
**********************************************************

Feb 11, 2013 Southern ITS International, Inc. Announces Negotiations for Major Network Infrastructure Contract
read full: http://finance.yahoo.com/news/southern-international-inc-announces-negotiations-180000643.html
**********************************************************

Feb 11, 2013 Southern ITS International, Inc. Completes Its Reorganization
read full: http://finance.yahoo.com/news/southern-international-inc-completes-reorganization-130000606.html
**********************************************************

Oct 22, 2012 Southern ITS International, Inc. Takes Steps to Become Fully Reporting
read full: http://finance.yahoo.com/news/southern-international-inc-takes-steps-215911713.html
**********************************************************

charts



company info

ticker: $SITS
CIK code: 0001468978
company name: Southern ITS International Inc.
company website: http://www.sitsint.com
incorporated In: NV, USA
sos filings: http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=k6cVhh9%252fGExLU3SkbfiR6w%253d%253d
edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001468978&owner=exclude&count=40
latest filings: http://www.otcmarkets.com/stock/SITS/filings
latest financials: http://www.otcmarkets.com/stock/SITS/financials
latest news: http://www.otcmarkets.com/stock/SITS/news - http://finance.yahoo.com/q/h?s=SITS+Headlines
major holdings: http://data.cnbc.com/quotes/SITS/tab/8.1
insider transactions: http://finance.yahoo.com/q/it?s=SITS+Insider+Transactions - http://www.secform4.com/insider-trading/SITS.htm

last known share structure

Shares Outstanding: 348,217,382 a/o Feb 04, 2013
Float: 146,816,982 a/o Feb 04, 2013
Authorized Shares: 500,000,000 a/o Feb 04, 2013
Par Value: Not Available

business description

The Company's operations consist of providing turnkey integration of electronic security systems for various types of industries, such as transportation, gaming and other secure operations in both government and private sectors. The integration includes surveillance, access control, network infrastructure, data com and fire and burglar alarm systems. Today, security technologies are evolving rapidly and require remote access through various networks, firewalls and internet security. Surveillance systems and access control are all network-dependent and work best for the end user when they are completely integrated. The Company's mission is to provide a complete integration of the various electronic security systems with the computer networks that they are dependent upon and enuring that the systems will remain secure from potential cyber attack.

TLFX--- Ready to BOUNCE right now!

OPXA, Opexa Therapeutics Closes Secured Note FinancingLast update: 7/26/2012 8:30:03 AMFocuses on Initiation of Phase IIb Trial in SP-MS THE WOODLANDS, Texas, Jul 26, 2012 (BUSINESS WIRE) -- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today announced the closing of a private offering of convertible secured promissory notes and warrants to purchase shares of common stock for gross proceeds of approximately $4 million. Opexa expects to use proceeds from the financing to commence its planned Phase IIb clinical study of Tcelna(TM) in patients with Secondary Progressive MS (SP-MS). Participating in the financing were new investors and existing shareholders, including members of Opexa's Board of Directors. "We are grateful for the support of our existing shareholders and their continued belief in the Company, along with the new investors who have joined this offering," commented Neil K. Warma, Opexa's President and CEO. "This capital should allow us to commence our planned Phase IIb clinical trial in SP-MS patients following the final review of our CMC submission by the FDA, which is expected shortly. The enthusiasm that has been generated by the MS community anticipating the start of this trial has been remarkable. It is a testament to what we believe is the true potential of the novel therapy we are developing and the impact it could have in addressing the significant unmet need of MS patients." Mr. Warma added, "Initiating the trial will be a key milestone for the Company, allowing us to implement the many improvements we have made to the manufacturing process and clinical trial design. This financing should allow us to make meaningful progress with patient recruitment as well as continue to advance ongoing discussions with potential partners. Our planned clinical trial is expected to involve 180 patients, each receiving two annual courses of Tcelna treatment, with each course consisting of five subcutaneous injections per year. In order to continue the clinical study once commenced, we will need to secure a substantial amount of additional financing through a potential partnership or additional capital raises, or both." The notes mature on July 25, 2014 and accrue interest at the rate of 12% per annum, compounded annually. Interest is payable semi-annually in either cash or registered shares of common stock at the Company's election. The notes are secured by substantially all of the Company's assets and are convertible into a new series of non-voting Convertible Preferred Stock. The notes can be converted at the option of the investors, subject to certain limitations and adjustments. Additionally, the Company can elect to convert the notes if (i) the Company's common stock closes at or above $2.50 per share for 20 consecutive trading days or (ii) the Company achieves certain additional funding milestones to continue its clinical trial program. The Convertible Preferred Stock accrues dividends at the rate of 8% per annum, which are cumulative and payable semi-annually in either cash or registered shares of the common stock at the Company's election. The Convertible Preferred Stock is convertible into shares of the Company's common stock at the option of the investors at a price of $0.80 per share, subject to certain limitations and adjustments. Additionally, the Company can elect to convert the Convertible Preferred Stock if Opexa's common stock closes at or above $4.00 per share for 20 consecutive trading days. The warrants have an exercise price of $1.25 per share, a five-year term, and are exercisable for 75% of the number of shares of common stock into which the notes are ultimately convertible, subject to certain limitations and adjustments. The Company can redeem the warrants at $0.01 per share if the Company's common stock closes at or above $2.50 per share for 20 consecutive trading days. A portion of the funds will be maintained in a controlled account as part of the security interest granted by the Company to the investors. The Company committed to file a registration statement to register the underlying shares of common stock as soon as practicable. About Opexa Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company's leading therapy, Tcelna(TM), a personalized cellular immunotherapy treatment, is in clinical development targeting both SP-MS and Relapsing Remitting MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. For more information, visit the Company's website at . Cautionary Statement Relating to Forward - Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "expects," "believes," "anticipates," "estimates," "may," "could," "should," "intends," and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the development of the Company's product candidate, Tcelna, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our capital position, the rights and preferences provided to the Series A Convertible Preferred Stock and investors in the notes (including a secured interest in all of the Company's assets) and the regulatory efficiency of the Company's operations and ongoing ability to obtain additional financing, the ability of the Company to enter into and benefit from a partnering arrangement for the Company's product candidate, Tcelna, on reasonably satisfactory terms (if at all), our dependence (if partnered) on the resources and abilities of any partner for the further development of Tcelna, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of developing a marketable product, our ability to raise additional capital to continue our treatment development programs and to undertake and complete any further clinical studies for Tcelna, the success of our clinical trials, the efficacy of Tcelna for any particular indication, such as Relapsing Remitting MS or Secondary Progressive MS, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna), the risk of litigation regarding our intellectual property rights, the success of third party development and commercialization efforts with respect to products covered by intellectual property rights that the Company may license or transfer, our limited manufacturing capabilities, our dependence on third-party manufacturers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011. SOURCE: Opexa Therapeutics, Inc. Neil K. Warma
Opexa Therapeutics, Inc.
President & CEO
281-775-0600
nwarma@opexatherapeutics.com

Copyright Business Wire 2012

It sure made a big move today.

OPXA at .70 +.315, hopefully something big coming to put my warrants into the money

BZRT - bouncing

in some FES 4.25, see recent qtr and listen to this: http://www.wsw.com/webcast/ghs3/fes/

MYOS is actually on the up swing...just posting here, cause the momenum that it's showing...it may continue for a while...up 22% today alone...

This is more of a long-term bounce, just starting:

added opxa today .52.. i think it's overdue for the partner or funding announcement

OPXA, sounds like they are still searching for a partner or funding, "In order to initiate the trial, we will need to secure additional financing, either through a potential partnership or additional capital raise, and this continues to be an important focus for us.”
"

More MGM @ 13.00 BYD @ 7.82

Back in MGM @ 13.69

Got some PWAV @1.32. eom

Out MGM @ 14.07 from 13.70

Just following up on OKOFF...dropped down to 1.10 PS after Pan America pulled out...and now back up with a PR today to 1.25 PS...news today that there will be press confernce to share holders of future plans tomorrow at 9am...
If anything good comes out...possible chance of returning to normal average of 1.75...or even back to 2.50 PS...

opxa .50 now.. i've abandoned hopes of a pharma partner now.. seems pretty obvious they are walking it down for a placement

going to hold .. may avg down

opxa at .60 level now.. didn't expect it to get here.. at this point i'm assuming it's going to be a placement vs a partnership with pharma

time will tell... holding with a .728 avg

OK...I have had nothing but BAD luck with mines and drilling...but, OKOFF just dropped today by 35%...looks like the only news is that company, Pan Americia, just backed out of their deal to provide a study...thus, releasing OKOFF from sharing 55% of the earnings...granted, the study may have found that there is no silver in the mine at all, but the only info in the PR states that there wasn't enough to benifit Pan Americia to continue doing buisness...
Just something to keep an eye on....I know that whatever happens, it most likely won't happen quickly....just keep an eye out...IMHO

In MGM again @ 13.70

nice job Duce

Out BYD @ 8.41 from 7.75

they did a conf call earlier in the year and it sounded really positive and brought in volume... they've been hiring and brought in a CRO

all signs point to their phaseIIb trial going forward

BIIIG question is whether they do a stock offering or partner with big pharma

i think the drifting is a combo of uncertainty and shorts


if it does a placement i wouldn't think it would be lower than .60.......'if' they partner with a big pharma.. i think it's an overnight doubler

ALL IMO of course

g/l

Looks like it has decent support there.

add more opxa .7199, hope i'm right that this is bottom

added opxa .7111

in OPXA .76

Out RAD at 2$ eom.

Will do!